Cysteine mutagenesis improves the production without abrogating antigenicity of a recombinant protein vaccine candidate for human chagas disease

• المؤلفون الرئيسيون: Christopher A. Seid (مؤلف), Kathryn M. Jones (مؤلف), Jeroen Pollet (مؤلف), Brian Keegan (مؤلف), Elissa Hudspeth (مؤلف), Molly Hammond (مؤلف), Junfei Wei (مؤلف), C. Patrick McAtee (مؤلف), Leroy Versteeg (مؤلف), Amanda Gutierrez (مؤلف), Zhuyun Liu (مؤلف), Bin Zhan (مؤلف), Jonathan L. Respress (مؤلف), Ulrich Strych (مؤلف), Maria Elena Bottazzi (مؤلف), Peter J. Hotez (مؤلف)
• التنسيق: كتاب
• منشور في: Taylor & Francis Group, 2017-03-01T00:00:00Z.
• الموضوعات: article
• الوصول للمادة أونلاين: Connect to this object online.

A therapeutic vaccine for human Chagas disease is under development by the Sabin Vaccine Institute Product Development Partnership. The aim of the vaccine is to significantly reduce the parasite burden of Trypanosoma cruzi in humans, either as a standalone product or in combination with conventional...